Quisel John D, CEO, reported an open-market or private sale at Disc Medicine, Inc. involving 11888.000000 shares for an estimated $949161.70. Reported holdings after the transaction were 226064.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
Chief Executive Officer
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.50 to $78.49, inclusive. The Reporting Person undertakes to provi…
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.53 to $79.52, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.53 to $80.02, inclusive.
The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date.
0 other filings
0 recent txs